Evotec and APEIRON Biologics start next project on the Cbl-b target

Thursday, 20. October 2011 07:27
Evotec AG /
Evotec and APEIRON Biologics start next project on the Cbl-b target
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany -20 October 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) and Apeiron Biologics AG today announced that they have entered into a
further discovery project on the Cbl-b target, an excellent target for anti-
tumor immune therapy.

Cbl-b plays a role in both the adaptive and the innate immune system and its
manipulation therefore can effectively enhance anti-tumor activities both for
tumor antigen-specific cells and for those recognizing general features of tumor
cells.

Evotec will apply their skills and proprietary technologies in cellular assay
development and ultra-high throughput screening (uHTS) to identify biologically
active molecules from its corporate library that interact with Cbl-b. The aim of
the collaboration will be to take compounds identified by Evotec as being active
against this target or other relevant targets and further jointly optimize them
as basis for formal preclinical and clinical development.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are very
pleased to start a new project with Apeiron. It is strategically important to be
involved in high promising early stage biotech projects."

Dr Hans Loibner, Chief Executive Officer at Apeiron Biologics, commented:
"Apeiron's substantial expertise in applied immunology and cancer immunotherapy
plus Evotec's remarkable skills in high-throughput methodology are an excellent
basis for the successful identification and development of novel drugs that
enhance the power of the immune system to combat cancer. This growing area has
major clinical and commercial potential. "

No financial details are disclosed.

Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions or
circumstances on which any such statement is based.






--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


PDF_of_Press release:
http://hugin.info/131215/R/1556374/480270.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1556374]
Related Links: Evotec SE, 
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.